Shares of Prothena Co. PLC (NASDAQ:PRTA) have received a consensus rating of “Hold” from the six research firms that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $13.26.

Several equities research analysts have commented on the stock. BidaskClub upgraded shares of Prothena from a “hold” rating to a “buy” rating in a research note on Saturday, March 16th. Cantor Fitzgerald assumed coverage on shares of Prothena in a research note on Monday, March 4th. They issued an “overweight” rating and a $13.77 price target on the stock. Finally, Zacks Investment Research upgraded shares of Prothena from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Wednesday, February 13th.

Large investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company increased its stake in shares of Prothena by 111.1% during the first quarter. The Manufacturers Life Insurance Company now owns 26,367 shares of the biotechnology company’s stock valued at $320,000 after acquiring an additional 13,879 shares during the period. State of Wisconsin Investment Board increased its stake in shares of Prothena by 29.6% during the first quarter. State of Wisconsin Investment Board now owns 53,800 shares of the biotechnology company’s stock valued at $653,000 after acquiring an additional 12,300 shares during the period. Swiss National Bank increased its stake in shares of Prothena by 3.1% during the first quarter. Swiss National Bank now owns 72,600 shares of the biotechnology company’s stock valued at $881,000 after acquiring an additional 2,200 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Prothena by 32.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,683,359 shares of the biotechnology company’s stock valued at $20,418,000 after acquiring an additional 410,527 shares during the period. Finally, DekaBank Deutsche Girozentrale increased its stake in shares of Prothena by 22.1% during the first quarter. DekaBank Deutsche Girozentrale now owns 15,450 shares of the biotechnology company’s stock valued at $240,000 after acquiring an additional 2,800 shares during the period.

Shares of NASDAQ:PRTA opened at $9.59 on Friday. Prothena has a 52 week low of $8.63 and a 52 week high of $17.60. The company has a market capitalization of $382.31 million, a price-to-earnings ratio of -2.66 and a beta of 2.40. The company has a current ratio of 27.85, a quick ratio of 28.90 and a debt-to-equity ratio of 0.07.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.08. Prothena had a negative net margin of 13,978.88% and a negative return on equity of 33.45%. The company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.20 million. Sell-side analysts predict that Prothena will post -2.44 EPS for the current year.

About Prothena

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.

Featured Article: Institutional Investors

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.